The role of Helicobacter pylori in the development of small intestinal bacterial overgrowth syndrome

Kolmogorova T.O.; Anchikova T.A.

doi:https://doi.org/10.17116/dokgastro2019803112

Kolmogorova T.O.

Joint-Stock Company Clinical Medical and Sanitary Unit 'Energetik', Kemerovo, Russia

Anchikova T.A.

Joint-Stock Company Clinical Medical and Sanitary Unit 'Energetik', Kemerovo, Russia

The role of Helicobacter pylori in the development of small intestinal bacterial overgrowth syndrome

Authors:

Kolmogorova T.O., Anchikova T.A.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2019;8(3): 12‑19

DOI: 10.17116/dokgastro2019803112

Read: 10526 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kolmogorova TO, Anchikova TA. The role of Helicobacter pylori in the development of small intestinal bacterial overgrowth syndrome. Russian Journal of Evidence-Based Gastroenterology. 2019;8(3):12‑19. (In Russ.)
https://doi.org/10.17116/dokgastro2019803112

Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Evaluating the efficacy of the Kyoto classification of gastritis in diagnosing Helicobacter pylori infection. Russian Journal of Evidence-Based Gastroenterology. 2025;(1):29-38

Comorbid conditions in gastric malignancies and their management in patients of the Northwestern federal district. Russian Journal of Evidence-Based Gastroenterology. 2025;(4):76-84

Abstract:

Objective — to study the role of Helicobacter pylori (HP) in the development of small intestinal bacterial overgrowth syndrome (SIBO) in residents of the Siberian region, as well as to determine the parameters of the most optimal and affordable method for screening of this pathology. Material and methods. A prospective study has enrolled 205 patients for 2018. Patients were divided into 2 groups depending on the presence or absence of SIBO syndrome: group 1 — 89 (43.4%) patients with SIBO syndrome; group 2 — 116 (56.6%) patients without SIBO syndrome. To conduct a respiratory test, a patient received carbohydrate substrate on an empty stomach. Then, hydrogen and methane concentrations were measured in exhaled air every 15 minutes for the next 90 minutes. Results. A positive result for the presence of HP was obtained in 66 (74.2%) patients of the 1st st group and the 36 (31.0%) patients of the 2nd group (p<0.001). Significant between-group differences were also observed in the quantitative analysis of HP (p<0.001). A negative result for the presence of HP was obtained in 23 (25.8%) patients of the 1st group and 80 (69.0%) patients of the 2nd group. Single HP was found in 31 (34.8%) patients of the 1st group and 20 (17.2%) patients of the 2nd group, moderate amount of HP — in 15 (16.9%) and 8 (6.9%) patients, large amount — in 20 (22.5%) and 8 (6.9%) patients, respectively. Conclusion. Patients with Helicobacter pylori infection are the most susceptible to SIBO syndrome. HP can, directly and indirectly, cause the disease, for example, during the treatment of disease provoked by HP. Gastroesophageal reflux disease and erosive gastritis are associated with the greatest risk because proton pump inhibitors are required in these patients for HP eradication. It should be noted that there is still no highly sensitive available non-invasive method for the diagnosis of SIBO syndrome. Therefore, further searching for the new tests and biomarkers, which would be valuable to diagnose SIBO syndrome, is required.

Keywords:

small intestinal bacterial overgrowth syndrome

Helicobacter pylori

respiratory test

hydrogen

methane

erosive gastritis

small intestinal bacterial overgrowth syndrome

Helicobacter pylori

respiratory test

hydrogen

methane

erosive gastritis

Authors:

Kolmogorova T.O.

Joint-Stock Company Clinical Medical and Sanitary Unit 'Energetik', Kemerovo, Russia

Anchikova T.A.

Joint-Stock Company Clinical Medical and Sanitary Unit 'Energetik', Kemerovo, Russia

Close metadata

References:

Konrad P, Chojnacki J, Gąsiorowska A, Rudnicki C, Kaczka A, Chojnacki C. Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. Przegląd Gastroenterologiczny. 2018;13(3):213-217. https://doi.org/10.5114/pg.2018.74228
Ghoshal UC, Shukla R, Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut and Liver. 2017;11(2):196-208. https://doi.org/10.5009/gnl16126
Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. American Journal of Gastroenterology. 2017;112(5):775-784. https://doi.org/10.1038/ajg.2017.46
Wilder-Smith CH, Olesen SS, Materna A, Drewes AM. Repeatability and effect of blinding of fructose breath tests in patients with functional gastrointestinal disorders. Neurogastroenterology and Motility. 2019;31(2):e13497. https://doi.org/10.1111/nmo.13497
Suri J, Kataria R, Malik Z, Parkman HP, Schey R. Elevated methane levels in small intestinal bacterial overgrowth suggests delayed small bowel and colonic transit. Medicine (Baltimore). 2018;97(21):e10554. https://doi.org/10.1097/MD.0000000000010554
Quigley EMM. The Spectrum of Small Intestinal Bacterial Overgrowth (SIBO). Current Gastroenterology Reports. 2019;21(1):3. https://doi.org/10.1007/s11894-019-0671-z
Del Zompo F, Ojetti V, Feliciani D, Mangiola F, Petruzziello C, Tesori V, Gaetani E, Gasbarrini A, Franceschi F. Helicobacter pylori infection is associated with high methane production during lactulose breath test. European Review for Medical and Pharmacological Sciences. 2016;20(16):3452-3456.
Enko D, Kriegshäuser G. Functional (13)C-urea and glucose hydrogen/methane breath tests reveal significant association of small intestinal bacterial overgrowth in individuals with active Helicobacter pylori infection. Clinical Biochemistry. 2017;50(1-2):46-49. https://doi.org/10.1016/j.clinbiochem.2016.08.017
Diaconu S, Predescu A, Moldoveanu A, Pop CS, Fierbințeanu-Braticevici C. Helicobacter pylori infection: old and new. Journal of Medicine and Life. 2017;10(2):112-117.
Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors. Current Gastroenterology Reports. 2017;19(8):42. https://doi.org/10.1007/s11894-017-0577-6
Paroni Sterbini F, Palladini A, Masucci L, Cannistraci CV, Pastorino R, Ianiro G, Bugli F, Martini C, Ricciardi W, Gasbarrini A, Sanguinetti M, Cammarota G,Posteraro B. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. Applied and Environmental Microbiology. 2016;82(22):6633-6644.
Chen B, Kim JJ, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. Journal of Gastroenterology. 2018;53(7):807-818. https://doi.org/10.1007/s00535-018-1476-9
Pérez AA, García Gavilán MC, Alcaide García J, Méndez Sánchez IM, Rivera Irigoin R, Fernández Cano F, Pereda Salguero T, Rivas Ruiz F. Small intestinal bacterial overgrowth is common after gastrectomy but with little impact on nutritional status. Gastroenterology Hepatology. 2019;42(1):1-10. https://doi.org/10.1016/j.gastrohep.2018.07.001
Zhilina AA, Luzina EV, Tomina EA, Pustotina ZM. The syndrome of excessive bacterial growth in the intestine is the current state of the problem. Rossijskiy meditsinskiy zhurnal. 2014;20:1:14-18. (In Russ.)
Erdogan A, Rao SS, Gulley D, Jacobs C, Lee YY, Badger C. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterology and Motility. 2015;27(4):481-489. https://doi.org/10.1111/nmo.12516
Hojo M, Asahara T, Nagahara A, Takeda T, Matsumoto K, Ueyama H, Matsumoto K, Asaoka D, Takahashi T, Nomoto K, Yamashiro Y, Watanabe S. Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors. Digestive Diseases and Sciences. 2018;63(11):2940-2949. https://doi.org/10.1007/s10620-018-5122-4
Parsons BN, Ijaz UZ, D’Amore R, Burkitt MD, Eccles R, Lenzi L, Duckworth CA,Moore AR, Tiszlavicz L, Varro A, Hall N, Pritchard DM. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. PLoS Pathogens. 2017;13(11):e1006653. https://doi.org/10.1371/journal.ppat.1006653
Yao X, Smolka AJ. Gastric Parietal Cell Physiology and Helicobacter pylori-Induced Disease. Gastroenterology. 2019:S0016-5085(19)32504-1. https://doi.org/10.1053/j.gastro.2019.02.036
Kulygina YuA, Makarova YuV, Krasner YaA, Osipenko MF. Excessive bacterial growth syndrome in patients after cholecystectomy for gastrointestinal tract with inflammatory bowel disease. Dokazatel’naya gastroenterologiya. 2018;7(1):55-56. (In Russ.)
Vakhrushev YaM, Lyapina MV, Lukashevich AP, Mikheeva PS. The role of excessive bacterial growth in dysfunction of the small intestine in patients with metabolic syndrome. Dokazatel’naya gastroenterologiya. 2018;7(10):91a-91. (In Russ.)
Gubergrits NB, Belyaeva NV, Lukashevich GM, Fomenko PG, Klochkov AE. The frequency of the syndrome of excessive bacterial growth in chronic pancreatitis. Dokazatel’naya gastroenterologiya. 2018;7(1):87b-88. (In Russ.)